ChemicalBook > CAS DataBase List > Cetuximab

Cetuximab

Product Name
Cetuximab
CAS No.
205923-56-4
Chemical Name
Cetuximab
Synonyms
EGFR antibody;IMC 225;Hsdb 7454;CETUXIMAB;CetuxiMab(C225);Unii-pqx0D8J21j;CETUXIMAB USP/EP/BP;Cetuximab (anti-EGFR);6-Diaminoheptanedioic acid;Cetuximab - Buffer solution
CBNumber
CB82448505
Molecular Formula
C107H179N35O36S7
Formula Weight
2756.23406
MOL File
205923-56-4.mol
More
Less

Cetuximab Property

storage temp. 
Store at 4°C, do not freeze
form 
Liquid
color 
Colorless to light yellow
More
Less

Safety

Hazardous Substances Data
205923-56-4(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

Usbiological
Product number
384860
Product name
Cetuximab
Packaging
96Tests
Price
$1114
Updated
2021/12/16
Biosynth Carbosynth
Product number
FC64978
Product name
Cetuximab - Buffer solution
Packaging
25mg
Price
$1500
Updated
2021/12/16
ChemScene
Product number
CS-7491
Product name
Cetuximab
Purity
99.70%
Packaging
25mg
Price
$2550
Updated
2021/12/16
ChemScene
Product number
CS-7491
Product name
Cetuximab
Purity
99.70%
Packaging
50mg
Price
$4080
Updated
2021/12/16
Biorbyt Ltd
Product number
orb86826
Product name
EGFR antibody
Purity
Sterile Filtration
Packaging
50μl
Price
$725.9
Updated
2021/12/16
More
Less

Cetuximab Chemical Properties,Usage,Production

Description

Cetuximab, a human/mouse chimeric monoclonal antibody that blocks the EGFR, was launched for use in combination with irinotecan in the treatment of patients with colorectal cancer who no longer respond to standard chemotherapy treatment with irinotecan. Cetuximab is obtained by chimerization of M225, a murine anti-EGFR antibody; specifically heavy and light chains of the murine antibody are cloned and adapted for expression with constant regions of the human kappa light chain and human gamma1 heavy chain. It is produced by mammalian (suspension) cells in serum-free medium, purified by protein A affinity chromatography, ion-exchange chromatography, and gel filtration. Cetuximab binds specifically to EGFR on both normal and tumor cells. Overexpression of the human EGFR is detected in many cancers, including those of the colon and rectum. The binding of cetuximab to EGFR prevents growth factors from binding to the receptor, thereby inhibiting cell growth and inducing apoptosis. The therapeutic regimen of cetuximab consists of an initial loading dose of 400 mg/m2 administered as a 120-min IV infusion, followed by weekly maintenance dose of 250 mg/m2 infused over 60 min. The steady-state plasma concentrations of cetuximab are reached by the third weekly infusion and the mean elimination half-life is 114 h. Cetuximab is eliminated by binding to EGFRs in various tissues, followed by internalization of the antibody- EGFR complex. Systemic clearance of the antibody is saturated at higher doses, and this appears to correlate with saturation of EGFR binding. In a multicenter clinical trial in more than 300 patients with advanced metastatic colorectal cancer, combination therapy with cetuximab and irinotecan produced response in more than half of the patients, shrinking tumors in 23% and stopping tumor growth in an additional 33% of the patients. The most common adverse reactions associated with cetuximab were acneform rash, asthenia/malaise, fever, nausea, abdominal pain, constipation and vomiting. Serious adverse events such as infusion reaction, fever, sepsis, kidney failure, dehydration and diarrhea were experienced by <10% of the patients.

Originator

ImClone (US)

Uses

Treatment of EGF receptor-expressing cancers (monoclonal antibod.

brand name

Erbitux

Mechanism of action

Cetuximab, a monoclonal antibody, binds to the extracellular domain of the EGFR, which is overexpressed in many human cancers, including head, neck, and colorectal types. This process prevents the EGFR from binding with its endogenous ligand, blocking the receptor-dependent transduction pathway and providing many antitumor effects involving cell-cycle arrest, induction of apoptosis, inhibition of angiogenesis, inhibition of metastasis, internalization, and downregulation of the EGFR, and enhancement of the sensitivity to radiochemotherapy[1].

Clinical Use

Monoclonal antibody:
Treatment of EGFR-expressing metastatic colorectal cancer in combination with irinotecan after failure of irinotecan-including cytotoxic therapy

Treatment of head and neck cancer

Toxicology

The majority of skin toxicities were mild to moderate, symptomatic treatments were effective in controlling them. The skin discomfort caused by cetuximab can affect the quality of life temporarily; with long term treatment, severity of skin toxicity may decrease.

Drug interactions

Potentially hazardous interactions with other drugs
Avoid with live vaccines.

Metabolism

Several pathways have been described that may contribute to the metabolism of antibodies. All of these pathways involve the biodegradation of the antibody to smaller molecules, i.e. small peptides or amino acids.

References

[1] W Bou-Assaly, S Mukherji. “Cetuximab (erbitux).” American Journal of Neuroradiology 31 4 (2010): 626–7.

Cetuximab Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Cetuximab Suppliers

Hefei Hirisun Pharmatech Co., Ltd.
Tel
+86-0551-62678551 +86-15056975894
Fax
0551-62678551
Email
sales@hirisunpharm.com
Country
China
ProdList
181
Advantage
55
Taizhou KEDE Chemical Co., Ltd
Tel
0576-84613060 13093829633
Fax
0576-84613060
Email
sales@kedechemical.com
Country
China
ProdList
298
Advantage
60
Shanghai Aladdin Biochemical Technology Co.,Ltd.
Tel
+86-18521732826
Email
market@aladdin-e.com
Country
China
ProdList
48461
Advantage
58
Shanghai Hanjing Chemicals Co., Ltd.
Tel
021-54285032 13641685631
Fax
+86 (21) 5443 7651
Email
gerry.shu@hanjingchemicals.com
Country
China
ProdList
76
Advantage
55
Wuhan Sunrise Technology Development Co., Ltd.
Tel
27-027-83314682 13554138826
Fax
+86 (27) 8331-4682
Email
whsrtech@vip.163.com
Country
China
ProdList
230
Advantage
62
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
6005
Advantage
61
LGM Pharma
Tel
1-(800)-881-8210
Fax
615-250-9817
Email
inquiries@lgmpharma.com
Country
United States
ProdList
2123
Advantage
70
Wuhan Fortuna Chemical Co., Ltd
Tel
027-59207852 13308628970
Fax
QQ3130921841
Email
buy@fortunachem.com
Country
China
ProdList
2866
Advantage
58
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
Country
China
ProdList
4727
Advantage
58
Beijing HuaMeiHuLiBiological Chemical
Tel
010-56205725
Fax
010-65763397
Email
waley188@sohu.com
Country
China
ProdList
12335
Advantage
58
More
Less

View Lastest Price from Cetuximab manufacturers

BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
Product
Cetuximab 205923-56-4
Price
US $0.00/g
Min. Order
1g
Purity
More Than 99%
Supply Ability
100kg/Month
Release date
2024-11-13
Dideu Industries Group Limited
Product
CETUXIMAB 205923-56-4
Price
US $1.10/g
Min. Order
1g
Purity
99.9%
Supply Ability
100 Tons Min
Release date
2021-07-02
Shaanxi Dideu Medichem Co. Ltd
Product
Cetuximab 205923-56-4
Price
US $0.00-0.00/Kg
Min. Order
1KG
Purity
99.0%
Supply Ability
800 ton
Release date
2020-04-30

205923-56-4, CetuximabRelated Search:


  • CETUXIMAB
  • Hsdb 7454
  • Immunoglobulin G1, anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 gamma1-chain), disulfide with human-mouse monoclonal C225 kappa-chain, dimer
  • Unii-pqx0D8J21j
  • CetuxiMab(C225)
  • EGFR antibody
  • IMC 225
  • Cetuximab - Buffer solution
  • Cetuximab (anti-EGFR)
  • CETUXIMAB USP/EP/BP
  • 6-Diaminoheptanedioic acid
  • Research Grade Cetuximab(DHB86902)
  • ImmunoglobulinG1, anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 g1-chain),disulfide with human-mouse monoclonal C225 k-chain, dimer
  • 205923-56-4
  • C6484H10042N1732O2023S36